A Novel, Potent, and Selective GABAA α5 Negative Allosteric Modulator for the Treatment of Cognitive Disorders
Recently, researchers have demonstrated enhancement of hippocampal memory function with orally active GABAA α5-selective NAM, avoiding the undesirable side effects associated with non-selective NAMs. The American Society for Pharmacology and Experimental Therapeutics published a journal article, “ONO-8590580, a Novel GABAA α5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models,” in 2018 and will publish a successive article later in 2020.
Watch our webinar to follow the journey of ONO-8590580 and learn how researchers identified a novel, orally active GABAA α5-selective NAM that improved hippocampal memory function and may offer therapeutic potential for the treatment of cognitive disorders, such as Alzheimer’s disease. Find out how researchers took a metabolically unstable hit compound through lead optimization, improving functional selectivity, ADME, and PK.